The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin i metabolism in aorta of apoE-knockout mice

Journal of Physiology and Pharmacology

Volumn 64, Issue 3, 2013, Pages

  Olszanecki, Rafal ^a   Suski, M ^a   Gebska, A ^a   Toton Zuranska, J ^a   Kus, K ^a   Madej, J ^a   Bujak Gizycka, B ^a   Jawien, J ^a   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin (1 7); ApoE knockout mice; Atherosclerosis; Mas receptor; Nebivolol; Nitric oxide; Renin angiotensin system

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; APOLIPOPROTEIN E; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NEBIVOLOL; ANGIOTENSIN I (1-7); ANGIOTENSIN I (1-9); ANTIHYPERTENSIVE AGENT; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; IMIDAZOLE DERIVATIVE; PEPTIDE FRAGMENT; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; EX VIVO STUDY; FEMALE; HORMONE METABOLISM; HORMONE SYNTHESIS; KNOCKOUT MOUSE; LIQUID CHROMATOGRAPHY; METABOLITE; MOUSE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WILD TYPE; AGONISTS; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DOWN REGULATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; METABOLISM; THORACIC AORTA;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZOPYRANS; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; IMIDAZOLES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; RENIN-ANGIOTENSIN SYSTEM; VASODILATOR AGENTS;

EID: 84895912806     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lu H, Balakrishnan A, Howatt DA, et al. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br J Pharmacol 2012; 165: 2000-2008.
2. Patarroyo Aponte MM, Francis GS. Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in atherosclerosis prevention. Curr Cardiol Rep 2012; 14: 433-442.
3. Durante A, Peretto G, Laricchia A, et al. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des 2012; 18: 981-1004.
4. Montero-Vega MT. The inflammatory process underlying atherosclerosis. Crit Rev Immunol 2012; 32: 373-462.
5. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-236.
6. Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32: 533-536.
7. Krskova K, Filipcik P, Zilka N, et al. Angiotensinogen and angiotensin-converting enzyme mRNA decrease and AT1 receptor mRNA and protein increase in epididymal fat tissue accompany age-induced elevation of adiposity and reductions in expression of GLUT4 and peroxisome proliferator-activated receptor (PPARgamma). J Physiol Pharmacol 2011; 62: 403-410.
8. Epstein BJ, Leonard PT, Shah NK. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. Expert Rev Cardiovasc Ther 2012; 10: 713-725.
9. Jugdutt BI. Nitric oxide and cardiovascular protection. Heart Fail Rev 2003; 8: 29-34.
10. Patel KP, Schultz HD. Angiotensin peptides and nitric oxide in cardiovascular disease. Antioxid Redox Signal 2012; May 21: (epub. ahead of print)
11. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 2012; 302: R518-R530.
12. Jawien J, Toton-Zuranska J, Kus K, Pawlowska M, Olszanecki R, Korbut R. The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis. Med Sci Monit 2012; 18: BR389-BR393.
13. Jawien J, Toton-Zuranska J, Gajda M, et al. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J Physiol Pharmacol 2012; 63: 77-85.
14. Kus K, Gajda M, Pyka-Fosciak G, et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60:163-165.
15. Toton-Zuranska J, Gajda M, Pyka-Fosciak G, et al. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2010; 61: 181-183.
16. Rath G, Balligand JL, Dessy C. Vasodilatory mechanisms of beta receptor blockade. Curr Hypertens Rep 2012; 14: 310-317.
17. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006; 24: 239-246.
18. Pawlowska M, Gajda M, Pyka-Fosciak G, et al. The effect of doxycycline on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2011; 62: 247-250.
19. Bujak-Gizycka B, Olszanecki R, Suski M, Madek J, Stachowicz A, Korbut R. Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol 2010; 61: 679-682.
20. Olszanecki R, Bujak-Gizycka B, Madej J, et al. Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol 2008; 59: 387-392.
21. Suski M, Gebska A, Olszanecki R, et al. Influence of atorvastatin on angiotensin I metabolism in resting and TNF-alpha-activated rat vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2013; Feb. 6 (epub ahead of print)
22. Nguyen Dinh CA, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides 2011; 32: 2141-2150.
23. Weiss D, Bernstein KE, Fuchs S, Adams J, Synetos A, Taylor WR. Vascular wall ACE is not required for atherogenesis in ApoE(-/-) mice. Atherosclerosis 2010; 209: 352-358.
24. Sui YB, Chang JR, Chen WJ, Zhao L, Zhang BH, Yu YR et al. Angiotensin-(1-7) inhibits vascular calcification in rats. Peptides 2013; 42C: 25-34. doi: 10.1016/j.peptides. 2012.12.023.:25-34.
25. Guang C, Phillips RD, Jiang B, Milani F. Three key proteases-angiotensin-I-converting enzyme (ACE), ACE2 and renin-within and beyond the renin-angiotensin system. Arch Cardiovasc Dis 2012; 105: 373-385.
26. Varagic J, Ahmad S, Voncannon JL, et al. Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 2012; 30: 1766-1774.
27. Yan W, Sheng ZM, Yu L. Nebivolol treatment improves resistant arterial function and reduces ventricular hypertrophy and angiotensin II in spontaneously hypertension rats. J Renin Angiotensin Aldosterone Syst 2013; 14: 146-155.
28. Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 16-21.
29. Comini L, Bachetti T, Cargnoni A, et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol Res 2007; 56: 42-48.
30. Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007; 56: 118-126.
31. Korystova AF, Emelyanov MO, Kublik LN, et al. Distribution of the activity of the angiotensin-converting enzyme in the rat aorta and changes in the activity with aging and by the action of L-NAME. Age (Dordr) 2012; 34: 821-830.
32. Sharifi AM, Akbarloo N, Darabi R. Investigation of local ACE activity and structural alterations during development of L-NAME-induced hypertension. Pharmacol Res 2005; 52: 438-444.
33. Linardi A, Panunto PC, Ferro ES, Hyslop S. Peptidase activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME). Biochem Pharmacol 2004; 68: 205-214.